EFSA flags health concerns over hydroxyanthracene in food

By Katy Askew

- Last updated on GMT

No 'safe limit' for consumption of hydroxyanthracene - EFSA ©iStock/AnnaIvanova
No 'safe limit' for consumption of hydroxyanthracene - EFSA ©iStock/AnnaIvanova

Related tags Nutrition Food European food safety authority

The European Food Safety Authority (EFSA) has confirmed it has “health concerns” over the use of hydroxyanthracene derivatives in food.

The European food safety watchdog warned that “some substances”​ belonging to the group of plant-based ingredients known as hydroxyanthracene derivatives “can damage DNA”​ and “may cause cancer”​ when added to food.

The EFSA concluded that certain hydroxyanthracene derivatives are genotoxic and said it is therefore not possible to set a “safe”​ daily intake. When tested in animal studies, some of these substances have also been shown to cause cancer in the intestine, the EFSA added.

This group of substances naturally occurs in plants such as aloe or senna species.

Health claim stands

An EFSA spokesperson stressed that the safety body warns against the prolonged use, or high levels of consumption, of foods containing hydroxyanthracene derivatives. However, the spokesperson also told FoodNavigator that the EFSA has approved a health claim for hydroxyanthracene derivatives. The EFSA found that hydroxyanthracene derivatives in food can improve bowel function.

“In 2013, EFSA substantiated a health claim related to hydroxyanthracene derivatives in food and improvement of bowel function, but advised against the long-term use and high doses due to potential safety concerns,”​ the spokesperson explained.

At the time, the EFSA’s Dietetic Products, Nutrition and Allergies (NDA) Panel noted: “stimulant laxatives should not be consumed continually for periods longer than one to two weeks”​ and “the use of stimulant laxatives for more than two weeks requires medical supervision”.

The European Commission subsequently asked EFSA to assess the safety of these plant ingredients when used in foods, and provide advice on a daily intake not associated with adverse health effects.

The EFSA’s latest assessment that it is impossible to set "safe"​ limits will now be passed to regulators, the spokesperson added. “In terms of next steps, EFSA’s advice will feed into discussions among the regulators – [the] European Commission and ​EU Member States.”

Green light for medicinal use

The medicinal use of hydroxyanthracene derivatives for the treatment of constipation remains approved by the European Medicines Agency.

According to EMA recommendations, the dose of hydroxyanthracene derivatives used in herbal medicinal laxative products should not exceed 30 mg per day for a maximum period of two weeks. Use is approved in in adults only and consumption is not recommended for pregnant and lactating women as well as in children.

Related news

Show more

Related products

show more

Discover Noochy Crisp® for health bars

Discover Noochy Crisp® for health bars

Content provided by Gnosis by Lesaffre USA | 23-May-2023 | Product Brochure

In the comfort food market, bars have a major place. Consumers are looking for healthier snacks and are more conscious of functional ingredients in their...

Immune support for everyone

Immune support for everyone

Content provided by Kerry | 16-May-2023 | Infographic

Consumers of all ages cite immune health as a top benefit driving their purchases, along with improving gut/digestive health.

H&F Pectin: Plant-based alternative to gelatine

H&F Pectin: Plant-based alternative to gelatine

Content provided by H&F – Innovative Solutions for your Product Developments | 12-May-2023 | Application Note

H&F Pectins are excellent as a plant-based alternative to gelatine in many applications.

Related suppliers

Follow us


View more